Mr. Conroy is the Chief Executive Officer (CEO) of ARTMS. Mr. Conroy brings to ARTMS more than 25 years of experience in the life sciences industry, including several significant senior positions within the radiopharmaceutical industry. Most recently Mr. Conroy was the General Manager of Jubilant Pharma where he was responsible for North American sales and operations. Prior to joining Jubilant, he was the Chief Operating Officer of PharmBlue LLC, a nationwide specialty pharmacy business focusing on the federal 340B drug program, retroviruses, mental and behavioral health, custom compounding, and pain management.

Previously, he was the Senior Director of Pharmacy Operations managing Express Scripts’ flagship pharmacy at the Technology and Innovation Center in St. Louis, Missouri. In that capacity, Mr. Conroy was responsible for launching the latest technology and refining operational processes to ensure that over 40 million prescriptions were filled annually. For his efforts, he was given the Chairman’s Award, a distinction given to only a handful of top performers. While at Express Scripts, Mr. Conroy also led UBC’s Patient Assistance Programs and Call Centers operations in St Louis, overseeing 1,200 clinical, clerical and administrative personnel who served over 50 different Pharma corporations.
Mr. Conroy has held a variety of roles with increasing responsibility at Amerinet (Intalere), Covidien, Eli Lilly and Nycomed Amersham (GE Healthcare).

Mr. Conroy earned a Bachelors in Science, Pharmacy from Purdue University and a Masters of Business Administration from the University of Michigan. Mr. Conroy was among the first to earn his Board Certification in Nuclear Pharmacy (BCNP) and is a registered pharmacist in 17 states.

Dr. Michael Cross

Chief Operating Officer

Dr. Michael Cross PhD, MBA, is the Chief Operating Officer of ARTMS and has responsibilities that include business and corporate development, strategy and operations. Dr. Cross has over 20 years of industry experience with a successful background in venture capital financing, operations and business development transactions.

Michael was the co-founder/COO/CBO of OncoSec Medical, an immuno-oncology company in San Diego. Before starting OncoSec Michael was the SVP and co-lead of a $330M Canadian life sciences venture fund. Michael has held senior positions at Viventia Biotech, MDS Proteomics, MDS Capital and the Toronto Raptors basketball team. Michael received his PhD in physiology from the University of Toronto and completed his post-doctoral training with the Department of Defence.



Dr. Paul Schaffer is CTO of ARTMS and Head of TRIUMF’s Life Sciences division. Paul came to TRIUMF in 2009 from the private sector where he worked at General Electric in upstate New York. He earned his Ph.D. in chemistry from McMaster University in 2003 and earned his B.Sc. with honours in chemistry and biochemistry from the University of British Columbia (UBC) in 1998. He is now also an adjunct professor at Simon Fraser University’s Department of Chemistry and an assistant professor in the Department of Radiology at UBC.

The commendations for Paul are many but he is most recognized for his earnest sincerity, his positive attitude, and his ability to create teams that produce phenomenal results on short time scales. A master of his subject matter, Paul has transformed the TRIUMF nuclear-medicine program by focusing on core competencies, specific outcomes, and connections with industrial and commercial interests.
Nigel S. Lockyer, former director of TRIUMF, commented, “Paul is a leader, an entrepreneur, an inspirational manager, and one of BC’s most promising talents. He is the key researcher looking forward for the laboratory and establishing the major nuclear-medicine research plans and goals for the next two decades.”

Jason S. Lewis, vice chair for research in the Department of Radiology at Memorial Sloan-Kettering Cancer Center, noted, “First and foremost, Paul is an outstanding and accomplished scientist. Not many achieve the level of performance, in terms of both research and leadership, as Paul has attained in his young career. He is a compelling and selfless leader of his team.”

Mr. Doug Gentilcore

Chief Commercial Officer

Mr. Doug Gentilcore is the Chief Commercial Officer of ARTMS and leads its sales/marketing efforts. Mr. Gentilcore has over 15 years of senior level sales in global radiopharmaceutical and imaging markets. Mr. Gentilcore was President of Implerem, a consulting firm focused on strategic and commercial solutions for the nuclear medicine industry. Prior to Implerem, he was the VP of Global Sales and Business Operations at Jubilant Radiopharma where he grew the sales/business operations team from a staff of 8 to over 70. Mr. Gentilcore has also held roles of increasing responsibility at Purview-Force 3, GE Healthcare, and Pfizer. Mr. Gentilcore has a BA in Business Economics from Randolph-Macon College.